Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

Core Insights - Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases through T cell-driven research [2] - The company will participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 28, 2024, featuring a fireside chat with key executives [1] Company Overview - Connect Biopharma specializes in T cell biology and drug discovery to create innovative therapies aimed at chronic inflammatory diseases, with a goal to improve the lives of millions globally [2] - The company is developing a pipeline of proprietary small molecules and antibodies, utilizing functional T cell assays to identify effective product candidates against validated immune targets [2] - The lead product candidate, rademikibart (formerly CBP-201), targets interleukin-4 receptor alpha (IL-4Rα) for treating atopic dermatitis and asthma [2] - The second product candidate, icanbelimod (formerly CBP-307), modulates S1P1 T cell receptors and is in development for ulcerative colitis [2]